Jun Shen, Min Zhou, Guangliang Zhu, Yu Zhang, Jinzhi Ma, Dekui Li, Lei Chen, Kejun Qi, Anjiang Wang, Yang Jiang, Zhiming Dai, Xiaoming Li
{"title":"右美托咪定用于改良电休克治疗：一项剂量优化治疗研究。","authors":"Jun Shen, Min Zhou, Guangliang Zhu, Yu Zhang, Jinzhi Ma, Dekui Li, Lei Chen, Kejun Qi, Anjiang Wang, Yang Jiang, Zhiming Dai, Xiaoming Li","doi":"10.1186/s40001-025-02509-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT).</p><p><strong>Methods: </strong>In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1-D5; 42/group). Groups D1-D5 received dexmedetomidine (0.2-1.0 μg/kg) 10 min pre-anesthesia, while controls received saline. Hemodynamic parameters heart rate (HR), mean arterial pressure (MAP), seizure duration, propofol requirements, recovery times, and adverse events were analyzed.</p><p><strong>Results: </strong>Doses ≥ 0.4 μg/kg (D2-D5) significantly reduced HR and MAP versus control (P < 0.05), with prolonged recovery in D4-D5 (P < 0.05). Seizure duration remained unchanged across groups. Propofol use decreased dose-dependently (D2-D5, P < 0.05). The D2 group (0.4 μg/kg) achieved optimal hemodynamic stability without excessive recovery delays.</p><p><strong>Conclusions: </strong>Dexmedetomidine pretreatment at 0.4 μg/kg optimizes MECT anesthesia by balancing hemodynamic control, reduced propofol use, and rapid recovery, establishing it as the recommended dose.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"241"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969942/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study.\",\"authors\":\"Jun Shen, Min Zhou, Guangliang Zhu, Yu Zhang, Jinzhi Ma, Dekui Li, Lei Chen, Kejun Qi, Anjiang Wang, Yang Jiang, Zhiming Dai, Xiaoming Li\",\"doi\":\"10.1186/s40001-025-02509-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT).</p><p><strong>Methods: </strong>In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1-D5; 42/group). Groups D1-D5 received dexmedetomidine (0.2-1.0 μg/kg) 10 min pre-anesthesia, while controls received saline. Hemodynamic parameters heart rate (HR), mean arterial pressure (MAP), seizure duration, propofol requirements, recovery times, and adverse events were analyzed.</p><p><strong>Results: </strong>Doses ≥ 0.4 μg/kg (D2-D5) significantly reduced HR and MAP versus control (P < 0.05), with prolonged recovery in D4-D5 (P < 0.05). Seizure duration remained unchanged across groups. Propofol use decreased dose-dependently (D2-D5, P < 0.05). The D2 group (0.4 μg/kg) achieved optimal hemodynamic stability without excessive recovery delays.</p><p><strong>Conclusions: </strong>Dexmedetomidine pretreatment at 0.4 μg/kg optimizes MECT anesthesia by balancing hemodynamic control, reduced propofol use, and rapid recovery, establishing it as the recommended dose.</p>\",\"PeriodicalId\":11949,\"journal\":{\"name\":\"European Journal of Medical Research\",\"volume\":\"30 1\",\"pages\":\"241\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969942/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40001-025-02509-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40001-025-02509-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study.
Objectives: To determine the optimal dexmedetomidine dose for hemodynamic stability and recovery quality in modified electroconvulsive therapy (MECT).
Methods: In this randomized trial, 252 patients receiving MECT were allocated to six groups (placebo, D1-D5; 42/group). Groups D1-D5 received dexmedetomidine (0.2-1.0 μg/kg) 10 min pre-anesthesia, while controls received saline. Hemodynamic parameters heart rate (HR), mean arterial pressure (MAP), seizure duration, propofol requirements, recovery times, and adverse events were analyzed.
Results: Doses ≥ 0.4 μg/kg (D2-D5) significantly reduced HR and MAP versus control (P < 0.05), with prolonged recovery in D4-D5 (P < 0.05). Seizure duration remained unchanged across groups. Propofol use decreased dose-dependently (D2-D5, P < 0.05). The D2 group (0.4 μg/kg) achieved optimal hemodynamic stability without excessive recovery delays.
Conclusions: Dexmedetomidine pretreatment at 0.4 μg/kg optimizes MECT anesthesia by balancing hemodynamic control, reduced propofol use, and rapid recovery, establishing it as the recommended dose.
期刊介绍：
European Journal of Medical Research publishes translational and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
